TORONTO, March 26, 2013 /CNW/ - Biosenta, Inc. (CNSX: ZRO) (the
"Company") is pleased to announce that it has entered into a
non-exclusive distribution agreement with New South Biolabs, LLC to
market and distribute the family of Zeromold products in the Southern
USA, Caribbean Basin and South America. In addition to the
non-exclusive distribution agreement, New South Biolabs will be
responsible for the enterprise resource planning [ERP], production and
customer relations management [CRM] within this territory. New South
Biolabs will also have the non-exclusive opportunity to manufacture
Zeromold within the territory. The distribution, sales and manufacture
of Zeromold in the various regions within the territory will only
commence in each jurisdiction once all regulatory and governmental
authorizations have been obtained for each such jurisdiction.
New South Biolabs will pay a $600,000 mobilization fee to Biosenta,
$300,000 of which was paid upon execution of the agreement. The second
payment of $300,000 is due when Biosenta receives confirmation of the
United States Environmental Protection Agency and the State of Florida
of Zeromold product registration. New South Biolabs has also agreed to
pay Biosenta a royalty equal to 30% of net profits from Zeromold
product sold by New South to its accounts within the territory after
New South Biolabs has recovered its fixed costs for the setup of the
ERP and CRM components . Biosenta will continue to make its profit
margin on the sale of all Zeromold products sold in the territory to
Biosenta house accounts and in respect of the sale of product to New
South Biolabs in its capacity as a distributor.
"This synergistic relationship has quickly borne fruit. The combined
teams have already begun to execute as expected and deliver the
logistics support and develop the marketing program for this territory"
said Bruce Lewis, President and Chief Executive Officer of Biosenta. He
added, "New South Biolabs presents a unique opportunity that will
enable our Company to penetrate the USA market with Zeromold products
in a geographic area that suffers heavily from black mould
About BIOSENTA Inc.
BIOSENTA Inc.'s line of retail anti-microbial products will effectively
kill mould, bacteria and fungi on contact and prevent re-growth. These
products address the demand created by the mounting health and
environmental concerns. Mould can affect the immune system, nervous
system, liver, kidneys, blood and cause brain damage.
BIOSENTA will also manufacture and distribute an anti-microbial filler.
Calcium Carbonate is one of the most common fillers used industrially.
It is susceptible like other fillers that hold moisture to attracting
mould. Annual global revenue in the calcium carbonate filler industry
approximates 140 billion dollars. BIOSENTA will produce anti-microbial
filler that performs 'filling' and 'bulking' functions like calcium
carbonate. BIOSENTA's filler product will not attract moisture and
consequently mould infestation. BIOSENTA's filler with its
anti-microbial high pH core in individual particles will enhance
commercial product life and eradicate a broad spectrum of known
bacteria, fungi, algae and other micro-organisms by suppression of
This release may contain forward-looking statements information and
statements which constitute "forward-looking information" under
Canadian securities law and which may be material regarding, among
other things, the Company's beliefs, plans, objectives, estimates,
intentions and expectations with respect to its capital and funding
plans. Inherent in the forward-looking information and statements are
known and unknown risks, uncertainties and other factors beyond the
Company's ability to control or predict, which give rise to the
possibility that the Company's predictions, forecasts, expectations or
conclusions will not prove to be accurate, that its assumptions may not
be correct and that the Company's plans, objectives and statements will
not be achieved. Actual results or developments may differ materially
from those contemplated by the forward-looking information and
statements. Consequently, undue reliance should not placed on such
On behalf of the Board of Directors of BIOSENTA Inc.
The CNSX has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved of the contents of
this press release. Neither the CNSX nor its Regulation Services
Provider (as such term is defined in the policies of the CNSX) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: BIOSENTA Inc.
For further information:
Bruce Lewis, President & Chief Executive Officer
1120 Finch Avenue West, Suite 503,
Toronto, Ontario M3J 3H7
(416) 410 2019
Investor Relations contact:
Investor Cubed Inc.